Emendo Biotherapeutics gets $61 million funding

US CRISPR gene-editing firm Emendo Biotherapeutics has announced a Series B $61 million investment led by Japanese biotech AnGes (TYO: 4563), reflecting its strategic interest in partnering with Emendo and increasing its stake in the company to 32%.

Emendo was founded in 2015 by OrbiMed and Takeda Ventures, the venture arm of Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502).

“This financing provides a strong foundation from which we can accelerate our proprietary OMNI gene editing platform towards a broad clinical pipeline for addressing devastating untreatable diseases,” said Dr David Barum, president and chief executive Emendo, adding: “We are grateful for such strong support from so many high-quality investors and strategic partners including AnGes, OrbiMed Advisors, OrbiMed Israel Partners and Takeda Ventures who share our vision to translate this powerful science into transformative medicines.”